PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Phil Skolnick, NIH Speak at Neuropsychiatric Conference September 13-14 San Francisco, California - Phil Skolnick at NIDA, NIH to speak at 2nd Neuropsychiatric conference Sept 13-14 San Francisco, California
Phil Skolnick, NIH Speak at Neuropsychiatric Conference September 13-14 San Francisco, California

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2012/06/29 - Phil Skolnick at NIDA, NIH to speak at 2nd Neuropsychiatric conference Sept 13-14 San Francisco, California.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Phil Skolnick, Director of the Division of Pharmacotherapies & Medical Consequences of Drug Abuse at NIDA, NIH will give a presentation on “Biological Approaches to Treat Substance Use Disorders” at the 2nd Neuropsychiatric Research and Development conference taking place on Sept 13-14, 2012 in San Francisco, CA.

Dr. Skolnick will describe passive and active immunization strategies directed against methamphetamine, nicotine, cocaine, and heroin as well as a bioengineered esterase that is capable of rapidly inactivating cocaine. Among the most compelling reasons to develop biologics is the promise of a long-lived protective effect, which requires the patient to make “one good decision” to receive a biologic, compared to one (or multiple) good daily decisions to remain compliant with a traditional medication.

His presentation will highlight:
• Recent advances in the development of biologics to treat SUDs;
• The strengths and limitations of biological approaches;
• Challenges in clinical trial design using biologics;
• Market opportunities for biologics in the treatment of SUDs.

Phil Skolnick is the Director, Division of Pharmacotherapies and Medical Consequences of Drug Abuse at the National Institute on Drug Abuse, NIH. Dr. Skolnick served as Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, Inc. He was also Research Professor of Psychiatry (2001-2009) and a member of the Center of Excellence on Drug Addiction at New York University-Langone Medical Center. Dr. Skolnick was a Lilly Research Fellow (Neuroscience) at Lilly Research Laboratories (1997-2000).

Dr. Skolnick’s awards and honors include the Experimental Therapeutics Prize from the American Society for Pharmacology and Experimental Therapeutics, an Anna Monika Prize, and the A.E. Bennett Award in Biological Psychiatry. He has twice been awarded the Doctor of Science, honoris causa. Dr. Skolnick has co authored more than 500 articles and currently serves on the editorial advisory boards of more than half a dozen journals. He is an editor of Current Protocols in Neuroscience and has edited six books, most recently, Glutamate-Based Approaches to Psychiatric Disorders (2010). The Institute of Scientific Information (ISI) has acknowledged his contributions by naming him to the elite group of “Highly Cited” authors.

GTC’s 2nd Neuropsychiatric Research and Development will discuss the latest breakthroughs, new drug targets, new models, neuroimaging, novel technologies and several other novel developments and therapeutics to combat neuropsychiatric disorders. The conference is also a part of the 2nd CNS Diseases World Summit. The Summit brings together the leading experts across the industry and academia to discuss the latest research and developments in the CNS field. The summit has four parallel tracks that focus on neurodegenerative conditions, neuropsychiatric disorders, pain research and therapeutics and CNS partneriing and deal-making.

Join your colleagues at this exciting Neuropsychiatric conference and CNS summit, and hear from and meet with key representatives in the field including Charles B. Nemeroff at University of Miami, Husseini Manji - Global Head of Neuroscience Therapeutic at Janssen, Barry Brand - Chief Executive Officer at CeNeRx, Michael W. Weiner at UCSF, George Garibaldi - Global Head of CNS Clinical Development at F. Hoffmann-La Roche, Tony W. Ho - Vice President at AstraZeneca, Michael C. Venuti, Chief Scientific Officer at NeuroTherapeutics Pharma, and many more!

For more information, please visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Phil Skolnick, NIH Speak at Neuropsychiatric Conference September 13-14 San Francisco, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)